Phio Pharmaceuticals Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Bob Bitterman
Chief executive officer
US$172.9k
Total compensation
| CEO salary percentage | 18.37% |
| CEO tenure | less than a year |
| CEO ownership | 0.2% |
| Management average tenure | no data |
| Board average tenure | 6.2yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2022 | US$173k | US$32k | -US$11m |
| Sep 30 2022 | n/a | n/a | -US$12m |
| Jun 30 2022 | n/a | n/a | -US$12m |
| Mar 31 2022 | n/a | n/a | -US$13m |
| Dec 31 2021 | US$78k | n/a | -US$13m |
| Sep 30 2021 | n/a | n/a | -US$12m |
| Jun 30 2021 | n/a | n/a | -US$11m |
| Mar 31 2021 | n/a | n/a | -US$10m |
| Dec 31 2020 | US$45k | n/a | -US$9m |
| Sep 30 2020 | n/a | n/a | -US$9m |
| Jun 30 2020 | n/a | n/a | -US$9m |
| Mar 31 2020 | n/a | n/a | -US$9m |
| Dec 31 2019 | US$64k | n/a | -US$9m |
| Sep 30 2019 | n/a | n/a | -US$8m |
| Jun 30 2019 | n/a | n/a | -US$7m |
| Mar 31 2019 | n/a | n/a | -US$7m |
| Dec 31 2018 | US$53k | n/a | -US$7m |
| Sep 30 2018 | n/a | n/a | -US$8m |
| Jun 30 2018 | n/a | n/a | -US$9m |
| Mar 31 2018 | n/a | n/a | -US$9m |
| Dec 31 2017 | US$36k | n/a | -US$12m |
| Sep 30 2017 | n/a | n/a | -US$15m |
| Jun 30 2017 | n/a | n/a | -US$15m |
| Mar 31 2017 | n/a | n/a | -US$14m |
| Dec 31 2016 | US$38k | n/a | -US$11m |
Compensation vs Market: Bob's total compensation ($USD172.93K) is below average for companies of similar size in the German market ($USD418.12K).
Compensation vs Earnings: Bob's compensation has increased whilst the company is unprofitable.
CEO
Bob Bitterman (71 yo)
Mr. Robert J. Bitterman, also known as Bob, serves as Chairman at Phio Pharmaceuticals Corp. since 2012 and has been its President and Chief Executive Officer since February 2023. Mr. Bitterman served as...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 10.8yrs | US$172.93k | 0.19% € 10.1k | |
| Director | 11yrs | US$129.86k | 0.18% € 9.6k | |
| Independent Director | 1yr | US$42.29k | no data | |
| Member of Scientific Advisory Board | 6.2yrs | no data | no data | |
| Independent Director | 10yrs | US$47.36k | 0.11% € 5.9k | |
| Member of Scientific Advisory Board | 5.9yrs | no data | no data | |
| Member of Scientific Advisory Board | 6.2yrs | no data | no data | |
| Lead Independent Director | 3.5yrs | US$57.99k | 0.17% € 8.8k | |
| Independent Director | 5.8yrs | US$39.86k | 0.11% € 5.9k |
Experienced Board: 44R0's board of directors are considered experienced (6.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/04/24 19:52 |
| End of Day Share Price | 2023/01/25 00:00 |
| Earnings | 2022/12/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Phio Pharmaceuticals Corp. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Maxim Jacobs | Edison Investment Research |
| Vernon Bernardino | H.C. Wainwright & Co. |